Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

---------------- EXPENSES License and royalty fees 2,568 - 2,568 Cost of products sold 25,682 (896) b 24,786 Research and development 6,833 (739) c 6,094 Selling, general and administrative 21,606 (2,548) d 19,058 Depreciation and amortization 8,296 (7,453) e 843 --------------------------------- --------------------------------------- 64,985 (11,636) 53,349 --------------------------------- --------------------------------------- Operating (loss) income (412) 11,238 10,826 --------------------------------- --------------------------------------- Other income (expenses): Foreign exchange (loss) gain (1,441) 1,441 f - Investment and other income (loss) (600) 636 g 36 Loss on sale/write-down of investments - - - Interest expense on long-term debt (9,641) 750 i (8,891) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (11,682) 2,827 (8,855) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (Loss) income before income taxes (12,094) 14,065 1,971 Income tax (recovery) expense (217) 3,960 j 3,743 --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- Net loss for the period (11,877) 10,105 (1,772) --------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB ; ... the acquisition, development and commercialization of,therapeutics for the ... hepatitis C, today announced the receipt on August ... that, according to the,Company,s financial statements for the ...
... Compounds ... in Merck KGaA Pipeline, ... and development company, announced today that,it will collaborate with Merck ... applications for drug candidates. KineMed,s,proprietary pathway-based drug discovery and development ...
... IVD Revenue Exceeded HIFU Revenue ... FY2007 Annual Targets Under ... Inc. (the "Company") (Nasdaq: CMED ), a leading ... in-,vitro diagnostic products and high intensity focused ultrasound tumor,therapy ...
Cached Biology Technology:XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market 2XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market 3KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 2China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... clumps of protein found within nerve cells are ... were first identified in the early 1900s by German ... in a protein called tau cause it to aggregate ... Normally, the tau protein is involved in the formation ...
... in the mainland United States known for its tropical smell now ... house ants - so called because they tend to invade houses ... to Hawaii. And, according to Purdue University entomologist Grzegorz Buczkowski, it ... "Odorous house ants in Hawaii are not like they are ...
... Mich. Discovering new treatments and battling dangerous infections ... targeting the genetic disorder cystic fibrosis with projects funded ... studies, with support from a $110,000 grant from Hunt ... Translational Sciences Institute, expand the relationship between the two ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Pesky ants found in Hawaii demonstrate invasive characteristics 24 projects target cystic fibrosis with Hunt for a Cure funds 2
... offers a full length insert sequencing service ... cosmids and fosmids. Agencourt utilizes unique ... libraries. There are several features that ... data with rapid turnaround including our patented ...
...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
A flexible 24-48 hour DNA sequencing service. Samples may be shipped in standard 1.5mL tubes. Oligo synthesis and DNA preparation available. Read lengths up to 850 Phred 20 bases. Universal primers p...
Biology Products: